The life sciences industry is converging.
As regulatory expectations rise and AI moves from experimentation to execution, leading pharma and medical device organizations are rethinking how quality, manufacturing, and asset management work together.
We’ve just published a new 2026 Life Sciences Industry Trends Brief that explores:
- Why siloed systems are no longer viable in a risk-based regulatory world
- How unified digital ecosystems are becoming the foundation for compliance and resilience
- Where AI is delivering real operational impact, from predictive maintenance to near-perfect quality inspections
- What regulatory modernization (QMSR, CSA, RRAs) means for digital readiness
If you’re responsible for quality, manufacturing, or operational excellence, this brief offers a clear view of what’s changing — and how leading organizations are responding.
Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.
By accessing this content, you are permitting EPR or a third party to contact you regarding the content (by phone or email).